Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. More Details
Excellent balance sheet and overvalued.
Share Price & News
How has Quanterix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: QTRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: QTRX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: QTRX exceeded the US Life Sciences industry which returned 51.9% over the past year.
Return vs Market: QTRX exceeded the US Market which returned 39.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Quanterix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHave Quanterix Corporation (NASDAQ:QTRX) Insiders Been Selling Their Stock?
1 month ago | Simply Wall StInvestors Who Bought Quanterix (NASDAQ:QTRX) Shares Three Years Ago Are Now Up 178%
4 months ago | Simply Wall StWhat Type Of Shareholders Make Up Quanterix Corporation's (NASDAQ:QTRX) Share Registry?
Is Quanterix undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: QTRX ($64.44) is trading above our estimate of fair value ($5.6)
Significantly Below Fair Value: QTRX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: QTRX is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: QTRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate QTRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: QTRX is good value based on its PB Ratio (5x) compared to the US Life Sciences industry average (6.9x).
How is Quanterix forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QTRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: QTRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: QTRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: QTRX's revenue (18.8% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: QTRX's revenue (18.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: QTRX is forecast to be unprofitable in 3 years.
How has Quanterix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QTRX is currently unprofitable.
Growing Profit Margin: QTRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: QTRX is unprofitable, and losses have increased over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare QTRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QTRX is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.1%).
Return on Equity
High ROE: QTRX has a negative Return on Equity (-6.37%), as it is currently unprofitable.
How is Quanterix's financial position?
Financial Position Analysis
Short Term Liabilities: QTRX's short term assets ($482.4M) exceed its short term liabilities ($36.5M).
Long Term Liabilities: QTRX's short term assets ($482.4M) exceed its long term liabilities ($24.7M).
Debt to Equity History and Analysis
Debt Level: QTRX's debt to equity ratio (1.6%) is considered satisfactory.
Reducing Debt: QTRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: QTRX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if QTRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Quanterix current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate QTRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate QTRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QTRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QTRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of QTRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
E. Hrusovsky (58 yo)
Mr. E. Kevin Hrusovsky has been Independent Chairman of the Board at 908 Devices Inc. since September 2020. He has been Chairman at Quanterix Corporation since June 10, 2014 and has been its Chief Executiv...
CEO Compensation Analysis
Compensation vs Market: E.'s total compensation ($USD3.52M) is about average for companies of similar size in the US market ($USD3.72M).
Compensation vs Earnings: E.'s compensation has been consistent with company performance over the past year.
Experienced Management: QTRX's management team is considered experienced (3.8 years average tenure).
Experienced Board: QTRX's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: QTRX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.3%.
Quanterix Corporation's company bio, employee growth, exchange listings and data sources
- Name: Quanterix Corporation
- Ticker: QTRX
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.342b
- Shares outstanding: 36.34m
- Website: https://www.quanterix.com
Number of Employees
- Quanterix Corporation
- Building 1
- 900 Middlesex Turnpike
- United States
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Mi...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/19 00:02|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.